Elevated hepatic enzymes potentially associated with sitagliptin

Annals of Pharmacotherapy

Volumn 44, Issue 2, 2010, Pages 394-395

  Gross, Benjamin N ^a,b   Cross, L Brian ^a,b   Foard, Joni ^a,b   Wood, Yelena ^c  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^b Holston Medical Group   (United States)

^c UCSD MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AMLODIPINE; BENAZEPRIL; CHONDROITIN; GLUCOSAMINE; HEMOGLOBIN A1C; INDOMETACIN; ROSUVASTATIN; SITAGLIPTIN;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CASE REPORT; CLINICAL ASSESSMENT; DRUG WITHDRAWAL; FOLLOW UP; HUMAN; LABORATORY TEST; LETTER; LIVER FUNCTION; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; PRIORITY JOURNAL; SIDE EFFECT;

ALANINE TRANSAMINASE; ASPARTATE AMINOTRANSFERASES; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; FATTY LIVER; HUMANS; LIVER; LIVER FUNCTION TESTS; MALE; MIDDLE AGED; PYRAZINES; TRIAZOLES;

EID: 76149095920     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1M323     Document Type: Letter

References (5)

1. Raz I, Hanefel M, Xu L, et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus. Diabetologia 2006;49:2564-71.
2. Aschner P, Kipnes MS, Lunceford JK, et al. Effects of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care 2006;29:2632-7.
3. Charbonnel B, Karasik A, Liu J, et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. Diabetes Care 2006;29:2638-43.
4. Goldstein BJ, Feinglos MN, Lunceford JK, et al. Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes. Diabetes Care 2007;30:1979-87.
5. Nauck MA, Meininger G, Sheng D, Terranella L, Stein PP. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial. Diabetes Obes Metab 2007;9:194-205.